⌕
Amphastar Pharmaceuticals · AMPH · Nasdaq
Tenet 67 · Solid
Compare
$29.10−0.24%At closeTenet 67 · Solid
$29.10−0.07 (−0.24%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Amphastar Pharmaceuticals (AMPH) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 1.7% in FY25, net margin 13.6%, and free cash flow (~$121.2M) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▼1.7%
719.9
FY21→FY25CAGR +13.2%/yr
Net income ($M)▼38.5%
98.1
FY21→FY25CAGR +11.6%/yr
Free cash flow ($M)▼29.7%
121.2
FY21→FY25CAGR +14.5%/yr
Diluted EPS▼33.7%
2.03
buyback-liftedCAGR +12.9%/yr
What the receipts whisper · what a headline number hides
Share count
−3.2%

49.8mn → 48.2mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$34.9M

−15.0% YoY in FY25 · 4.8% of revenue.

Returns vs FCF
62%

$75.6M returned vs $121.2M of FCF in FY25. Buybacks covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)719.9Revenue−363.8COGS356.1Gross profit−85.8R&D−85.9SG&A140.4Op income−42.3Tax & other98.1Net income

14¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.

Margin trend · direction beats level Gross Operating Net
604530150%sector median net margin ~3%FY21FY25

Over this window: gross 45.6% → 49.5%. Net margin 13.6% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
745.8719.9732.0644.4499.0437.8▼1.7%+13.2%
Cost of revenue
396.7363.8358.1293.3250.1238.0▲1.6%+11.2%
Gross profit
349.1356.1373.9351.1248.9199.7▼4.8%+15.5%
Research & development
92.385.873.973.774.860.9▲16.1%+8.9%
Selling, general & admin
69.685.956.751.545.151.4▲51.5%+13.7%
Total operating expenses
209.4215.7168.4154.1141.4129.9▲28.0%+13.5%
Operating incomefeeds ROC rank
139.7140.4205.4197.0107.569.9▼31.7%+19.1%
Other income, net
−10.2−16.8−15.7−25.68.514.3——
Pretax income
129.6123.6189.8171.4116.084.1▼34.9%+10.1%
Income tax
30.625.529.731.823.520.6▼14.0%+5.5%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
99.098.1159.5137.591.463.3▼38.5%+11.6%
Per share
Diluted EPSbuyback-sensitive
2.192.033.062.601.741.25▼33.7%+12.9%
Diluted shares (mn)
43.3848.2252.0653.0052.4349.78▼7.4%−0.8%
Margins
Gross margin26th pct in Healthcare
46.8%49.5%51.1%54.5%49.9%45.6%▼1.6pp+3.8pp
Operating margin
18.7%19.5%28.1%30.6%21.5%16.0%▼8.6pp+3.5pp
Net margin74th pct in Healthcare
13.3%13.6%21.8%21.3%18.3%14.5%▼8.2pp−0.8pp
† TTM = trailing four quarters through 2026-09-30.
FY12 – FY20 · 9 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 9 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Amphastar Pharmaceuticals' revenue last fiscal year?

Amphastar Pharmaceuticals reported revenue of $719.9M in fiscal 2025, down 1.7% from fiscal 2024.

What was Amphastar Pharmaceuticals' net income?

Amphastar Pharmaceuticals reported net income of $98.1M in fiscal 2025, a net margin of 13.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.